A collection of serum markers that accompany the onset of abnormal fat storage, specifically in the disproportionate deposition of visceral adipose tissue (VAT), have been associated with the pathology of insulin resistance. These blood levels have interrelated relationships in obesity-related disease pathology. Integrative physicians now understand that although individually these lab indicators may enter the health assessment picture at different times due to biochemical individuality, certainly metabolic syndrome is continuing to worsen along with the increased inability to shed excess weight easily. Over time the appearance of more and more of these particular serum markers continue to underscore the depth of the disease pathology that is pushing the patient closer to cardio-metabolic disorders and hormone related cancers, our number one and two causes of death.
These serum levels are as follows: elevated triglycerides, total cholesterol serum insulin; decreased HDL cholesterol and glucose tolerance.
Over time, insulin resistance progressively becomes more severe and continues to affect function of more organs. When serum glucose levels remain elevated, there is increased likelihood of protein glycosylation and overproduction of free-radical producing oxidative stress, which have proven association with initial central obesity, and eventual atherosclerosis, type II diabetes, heart disease and cancers. The body’s typical reaction of producing more and more insulin leads to insulin resistance in various locations throughout the body as disease progresses. In the skin, insulin resistance can be revealed as acne, while insulin resistance in the brain over time becomes Alzheimer’s—recently given the name Diabetes Type III.
The Serum Measures Chart above reflects that all serum risk factors tested for cardio-metabolic disorders were significantly reduced.
Physical measurements of subjects’ chest, waist and hips, before and after, reflected that all Slenderiiz-using subjects lost a significant amount of fat in the waist measurement, indicating decrease in visceral adipose tissue stores, as well as associated mortality risks of central obesity.
Within the first 4 weeks of the trial, several of the placebo subjects, though weight loss was reflected on the scale and visibly in the face and extremities, did not lose any inches from their waist measurement. One placebo subject, whose total loss goal at the onset of the trial was only 12 lbs, reported initial concern over the loss of significant inches in the chest and extremities, without any loss of weight in the midsection measures. After the crossover to the active Slenderiix, subject continued to lose the last few pounds to reach her goal, but also noticed a remarkable redistribution of normal body fat to the more desirable female areas, as her weight stabilized to a new set point during the remaining few weeks on the active product.
All Slenderiix-using groups reflected significant inches lost in the waist measurement, as compared to the chest and hips throughout every stage of the trial. This confirms the ability of the Slenderiiz program to target release of fat stores in the area of dangerous visceral adipose fat. Although the full extent of the mechanisms that allow this to be possible are yet unknown, serum tests reflect a regain in glycemic control, thus reversing the progression of insulin resistance—first heralded by the visible increase in visceral adipose tissue at the waist measurement—and the pathological risks that would have followed in time.
Typically, belly fat stores are protected by cortisol and other stress hormones in a season of calorie deficit, and studies have shown that these fat stores are typically only released after 90 days on an ultra-low calorie diet. The results of the Slenderiiz Weight Loss Program would suggest there is compensory interaction with these stress-related hormones. Exact mechanism of the action observed is yet undetermined, but would warrant further study in this area.
Cardio-metabolic Risk Assessors that accompany excess Visceral Adipose Tissue
Typically, as insulin secretion increases, blood triglycerides and glucose levels continue to rise, while HDL levels slowly decrease and VAT begins to accumulate. Since insulin is released in response to too much glucose in the blood, and HbA1c represents the amount of hemoglobin molecules that have had glucose molecules attached to them in the blood stream, these two serum markers typically rise and fall together. Serum levels of insulin within study subjects decreased an average of 27.7%, and correlating HbA1c also decreased 4.4%.
Even though all cholesterol levels were monitored and improved upon, the cholesterol values that are specific to indicate systemic inflammation are now accepted to be most pertinent to reversing the interrelated risks of heart disease and obesity.
The pathology of arterial plaque formation in heart disease has been proven to be caused by several factors effecting inflammatory response to the small vascular injuries that occur from a cascade of reactive events. Over-production of insulin from sugar and starch consumption, increased platelet adhesion due to omega 3 fat deficiency with omega 6/9 excess and antioxidant deficiency, emotional stress, all theses sources of oxidative stress contribute to inflammatory pathology. If inflammation is eliminated, arteries are clear, regardless of total cholesterol levels. Across all cholesterol markers, subjects responded with significant improvements in all areas.
The fraction of cholesterol that indicates potential endothelial inflammatory damage is called Very Low Density Lipoproteins (VLDL). Due to excessive free radical production, when cholesterol is oxidized into VLDL, it indicates an insufficient amount of antioxidants available within the body. VLDL can be significantly reduced by supplementing adequate vitamins, minerals and antioxidants, by modulating increases, beyond standard dosing, appropriate to the level of stress of the individual. This inflammatory marker, VLDL was significantly reduced.
The National Institutes of Health funded the VITAL study to asses the effect of vitamin D and omega 3 supplementation on the prevention of cancer and heart disease. (23) This was a large-scale randomized trial which also made correlations to fasting insulin, glucose, altered cholesterol ratios and the prevalence of metabolic syndrome. Findings proved that the lower the serum vitamin D, the more prevalent these inflammatory makers for insulin resistance progressing to metabolic syndrome. Increasing serum 25(OHD) is associated with a responsive lowering of VAT, triglycerides, triglyceride/HDL-cholesterol ratio. Within this trial period, subjects serum vitamin D increased an overage of 15.7% overall, raising serum levels of 9 out of 10 subjects to reflect an optimal range of 40-69 ng/ml, and the remaining subject at 39.10 ng/ml. Due to the seasonality of the trial beginning fall and ending mid-winter, these results are impressive, considering vitamin D levels typically plummet in winter months and fat stores simultaneously increase.
Higher levels of Highly Sensitive C-Reactive protein are linked to higher occurrences of sudden cardiac death, strokes, peripheral artery disease and myocardial infarction. HS-CRP is an inflammatory particle produced by the liver in response to stressors. Trial subjects averaged a 24% reduction in HS-CRP.
Since about 50% of all heart attacks and strokes effect people with normal total cholesterol levels, anti-aging medicine specialists now look to a combination assessment of the inflammatory HS-CRP along with the ratio of Triglycerides (TG) to High Density Lipoprotein (HDL) cholesterol to offer more effective proactive approaches to risk assessment. (22, 25, 26) As most triglycerides in the blood are indicative of carbohydrates that have been converted into fat that will be stored specifically in the visceral adipose tissue area, reducing serum levels of triglycerides and comparing these levels to sufficient quantity of HDL is a significant indicator of the degree of disease pathology, to identify the patient’s place on the continuum between insulin resistance and metabolic syndrome. (24)
Data from the Third National Health and Nutrition Examination Survey (NHANES III) indicated that the most frequently noted serum markers among overweight and obese adolescents are high TG (25–30% of adolescents) and low HDL cholesterol levels (40–50% of adolescents). (26)
The table below reflects the results of TG/HDL Ratio improvements within the 12 week period.